A
Alcista
Alcista · 25%CMND
$0.98
Precio del escenario
$5.580
-0.258 (-4.62%)Al cierre
Loading chart…
- Máximo
- 5.710
- Apertura
- 5.710
- Precio medio ponderado por volumen
- 5.56
- Volumen
- 13.14K
- Capitalización
- 4.44M
- Mínimo
- 5.400
- Importe
- 73.10K
- EV/EBITDA, TTM
- 0.00
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
Análisis de IA of Clearmind Medicine Inc (CMND)
VenderClearmind Medicine Inc. is not a good buy right now due to its significant financial losses and negative momentum. The current price is $5.58, which is down 96.49% year-to-date and 99.74% over the past year. The RSI is at 28.128, indicating that the stock is oversold, but this does not guarantee a price rebound. The company has reported a net income loss of $3,854,583 in Q1 2026 and has a forward P/E ratio of 0, indicating no expected earnings growth in the near future. The main risk is the ongoing financial losses, with a gross profit of -$14,218 in Q3 2026, suggesting that the company is struggling to generate revenue. Until there are clear signs of recovery or positive earnings, it is advisable to avoid this stock.
Métricas de valoración
El PER previsto actual de Clearmind Medicine Inc (CMND) es 0.00, frente a su media de 5 años de 0.00.
Escenarios de precio de Alphio AI para CMND
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.010-27NewsfilterClearmind Completes Patient Recruitment for CMND-100 Clinical Trial
- 8.510-09Newsfilter
Clearmind Advocates for New Regulatory Pathways for Neuroplastogens in AUD Treatment
8.509-26NASDAQ.COMClearmind Secures Three New Drug Combination Patents
- 8.509-22Newsfilter
Clearmind Medicine Testifies at FDA Hearing on Psychedelic Drugs
9.009-11Yahoo FinanceClearmind Enrolls First Patients in AUD Clinical Trial
Preguntas frecuentes sobre CMND, respondidas por Alphio AI
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Clearmind Medicine Inc. is not a good buy right now due to its significant financial losses and negative momentum. The current price is $5.58, which is down 96.49% year-to-date and 99.74% over the past year. The RSI is at 28.128, indicating that the stock is oversold, but this does not guarantee a price rebound. The company has reported a net income loss of $3,854,583 in Q1 2026 and has a forward P/E ratio of 0, indicating no expected earnings growth in the near future. The main risk is the ongoing financial losses, with a gross profit of -$14,218 in Q3 2026, suggesting that the company is struggling to generate revenue. Until there are clear signs of recovery or positive earnings, it is advisable to avoid this stock.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.